- Mumps has re-emerged as an infection in the developed world. Its epidemiology has changed, with the majority of cases now primarily affecting adolescents and adults.
While mumps is easily suspected if parotitis is present, parotitis is absent in 10%–30% of symptomatic cases.
Mumps is a systemic infection with a variety of extra-parotid complications.
In Australia, mumps diagnosis is confirmed by antibody testing and reverse transcriptase-polymerase chain reaction techniques. Suitable specimens for testing are serum, saliva, urine and cerebrospinal fluid.
Treatment is generally supportive, although intravenous immunoglobulin therapy may have a future role in mumps management. Interferon alpha-2b treatment may be considered specifically for mumps epididymo-orchitis.
Mumps vaccine is included in the measles–mumps–rubella (MMR) vaccine. In Australia, this vaccine is routinely administered at the ages of 1 and 4 years.
Serious reactions to the mumps components of the MMR vaccine are rare.
- 1. Mühlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol 2004; 4: 215-219.
- 2. Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccine coverage in Australia, 2003 to 2005. Commun Dis Intell 2007; 31 Suppl: S1-S152.
- 3. Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006; 24: 7037-7045.
- 4. Mumps virus vaccines. Wkly Epidemiol Rec 2007; 82: 51-60.
- 5. Gemmill IM. Mumps vaccine: is it time to re-evaluate our approach? CMAJ 2006; 175: 491-492.
- 6. Centers for Disease Control and Prevention. Update: multistate outbreak of mumps — United States, January 1–May 2, 2006. MMWR Morb Mortal Wkly Rep 2006; 55: 559-563.
- 7. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 2007; 13: 12-17.
- 8. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005; 330: 1132-1135.
- 9. Australian Department of Health and Ageing. National Notifiable Diseases Surveillance System. http://www9.health.gov.au/cda/Source/CDA-index.cfm (accessed Aug 2008).
- 10. Narita M, Matsuzono Y, Takekoshi Y, et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol 1998: 5: 799-803.
- 11. Nöjd J, Tecle T, Samuelsson A, Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001; 19: 1727-1731.
- 12. Atrasheuskaya AV, Kulak MV, Rubin S, Ignatyev GM. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002–2004. Clin Microbiol Infect 2007; 13: 670-676.
- 13. Singh R, Mostafid H, Hindley RG. Measles, mumps and rubella — the urologist’s perspective. Int J Clin Pract 2006; 60: 335-339.
- 14. Litman N, Baum SG. Mumps virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone, 2005: 2003-2008.
- 15. Campos-Outcalt D. Mumps epidemic in 2006: are you prepared to detect and prevent it? J Fam Pract 2006; 55: 500-502.
- 16. Gut JP, Lablache C, Behr S, Kirn A. Symptomatic mumps virus reinfections. J Med Virol 1995; 45: 17-23.
- 17. World Health Organization. WHO-recommended surveillance standard of mumps. http://www.who.int/immunization_monitoring/diseases/mumps_surveillance/en/index.html (accessed Aug 2008).
- 18. Centers for Disease Control and Prevention. Mumps case definition and case classification (CSTE). http://www.cdc.gov/nip/diseases/mumps/case-def.htm (accessed Aug 2008).
- 19. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet 2008; 371: 932-944.
- 20. Kawashima Y, Ihara K, Nakamura M, et al. Epidemiological study of mumps deafness in Japan. Auris Nasus Larynx 2005; 32: 125-128.
- 21. Taparelli F, Squadrini F, De Rienzo B, et al. Isolation of mumps virus from vaginal secretions in association with oophoritis. J Infect 1988; 17: 255-258.
- 22. Caranasos GJ, Felker JR. Mumps arthritis. Arch Intern Med 1967; 119: 394-398.
- 23. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol 2006; 21: 446-457.
- 24. Bajaj NP, Rose P, Clifford-Jones R, Hughes PJ. Acute transverse myelitis and Guillain-Barré overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand 2001; 104: 239-242.
- 25. Mandel L, Surattanont F. Bilateral parotid swelling: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 221-237.
- 26. Krause CH, Molyneaux PJ, Ho-Yen DO, et al. Comparison of mumps-IgM ELISAs in acute infection. J Clin Virol 2007; 38: 153-156.
- 27. Centers for Disease Control and Prevention. Mumps — laboratory testing for mumps infection Q & A. http://www.cdc.gov/vaccines/vpd-vac/mumps/outbreak/faqs-lab-test-infect.htm (accessed Aug 2008).
- 28. Uchida K, Shinohara M, Shimada S, et al. Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real-time PCR. J Med Virol 2005; 75: 470-474.
- 29. Forsberg P, Frydén A, Link H, Orvell C. Viral IgM and IgG antibody synthesis within the central nervous system in mumps meningitis. Acta Neurol Scand 1986; 73: 372-380.
- 30. Ukkonen P, Granström ML, Räsänen J, et al. Local production of mumps IgG and IgM antibodies in the cerebrospinal fluid of meningitis patients. J Med Virol 1981; 8: 257-265.
- 31. Poggio GP, Rodriguez C, Cisterna D, et al. Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases. J Clin Microbiol 2000; 38: 274-278.
- 32. Yeniyol CO, Sorguc S, Minareci S, Ayder AR. Role of interferon-alpha-2B in prevention of testicular atrophy with unilateral mumps orchitis. Urology 2000; 55: 931-933.
- 33. Erpenbach KH. Systemic treatment with interferon-alpha 2B: an effective method to prevent sterility after bilateral mumps orchitis. J Urol 1991; 146: 54-56.
- 34. Ku JH, Kim YH, Jeon YS, Lee NK. The preventive effect of systemic treatment with interferon-alpha2B for infertility from mumps orchitis. BJU Int 1999; 84: 839-842.
- 35. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: NHMRC, 2003. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-home (accessed Aug 2008).
- 36. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 1995; 13: 1617-1622.
- 37. Harling R, White JM, Ramsay ME, et al. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005; 23: 4070-4074.
- 38. Hinman AR, Irons B, Lewis M, Kandola K. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002; 80: 264-270.
- 39. World Health Organization. Global Advisory Committee on Vaccine Safety. Adverse events following mumps vaccination [Internet]. Geneva: WHO, 2003. http://www.who.int/vaccine_safety/topics/mumps/statement/en (accessed Aug 2008).
- 40. Toovey S, Jamieson A. Pancreatitis complicating adult immunisation with a combined mumps measles rubella vaccine. A case report and literature review. Travel Med Infect Dis 2003; 1: 189-192.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.